These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 21360131)

  • 1. Monoclonal antibodies for the treatment of severe asthma.
    Clienti S; Morjaria JB; Basile E; Polosa R
    Curr Allergy Asthma Rep; 2011 Jun; 11(3):253-60. PubMed ID: 21360131
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Monoclonal antibodies for chronic refractory asthma and pipeline developments.
    Polosa R; Casale T
    Drug Discov Today; 2012 Jun; 17(11-12):591-9. PubMed ID: 22306350
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A recombinant humanized anti-IgE monoclonal antibody (omalizumab) in the therapy of moderate-to-severe allergic asthma.
    D'Amato G; Piccolo A; Salzillo A; Noschese P; D'Amato M; Liccardi G
    Recent Pat Inflamm Allergy Drug Discov; 2007 Nov; 1(3):225-31. PubMed ID: 19075985
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.
    Solèr M; Matz J; Townley R; Buhl R; O'Brien J; Fox H; Thirlwell J; Gupta N; Della Cioppa G
    Eur Respir J; 2001 Aug; 18(2):254-61. PubMed ID: 11529281
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Anti-IgE in allergic asthma and rhinitis: an update.
    Morjaria JB; Gnanakumaran G; Babu KS
    Expert Opin Biol Ther; 2007 Nov; 7(11):1739-47. PubMed ID: 17961096
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Disabling inflammatory pathways with biologics and resulting clinical outcomes in severe asthma.
    Caruso M; Crisafulli E; Demma S; Holgate S; Polosa R
    Expert Opin Biol Ther; 2013 Mar; 13(3):393-402. PubMed ID: 23289846
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-IgE antibodies for the treatment of asthma.
    Buhl R
    Curr Opin Pulm Med; 2005 Jan; 11(1):27-34. PubMed ID: 15591885
    [TBL] [Abstract][Full Text] [Related]  

  • 8. IgE and eosinophils as therapeutic targets in asthma.
    Patel TR; Sur S
    Curr Opin Allergy Clin Immunol; 2017 Feb; 17(1):42-49. PubMed ID: 27906698
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treating moderate-to-severe allergic asthma with anti-IgE monoclonal antibody (omalizumab). An update.
    D'Amato G; Perticone M; Bucchioni E; Salzillo A; D'Amato M; Liccardi G
    Eur Ann Allergy Clin Immunol; 2010 Aug; 42(4):135-40. PubMed ID: 21114196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. What is new in antiimmunoglobulin E asthma therapy.
    Berger WE
    Allergy Asthma Proc; 2005; 26(6):428-34. PubMed ID: 16541964
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Targeted immunologic therapies for severe asthma].
    Humbert M; Garcia G; Chanez P
    Presse Med; 2008 Jan; 37(1 Pt 2):173-81. PubMed ID: 17980548
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modeling the effects of omalizumab over 5 years among patients with moderate-to-severe persistent allergic asthma.
    Grossman HL; Schlender A; Alperin P; Stanley EL; Zhang J
    Curr Med Res Opin; 2010 Dec; 26(12):2779-93. PubMed ID: 21050061
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of childhood asthma with anti-immunoglobulin E antibody (omalizumab).
    Milgrom H; Berger W; Nayak A; Gupta N; Pollard S; McAlary M; Taylor AF; Rohane P
    Pediatrics; 2001 Aug; 108(2):E36. PubMed ID: 11483846
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treating Moderate-to-Severe Allergic Asthma with a Recombinant Humanized Anti-IgE Monoclonal Antibody (Omalizumab).
    D'Amato G; Bucchioni E; Oldani V; Canonica W
    Treat Respir Med; 2006; 5(6):393-8. PubMed ID: 17154668
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE.
    Humbert M; Beasley R; Ayres J; Slavin R; Hébert J; Bousquet J; Beeh KM; Ramos S; Canonica GW; Hedgecock S; Fox H; Blogg M; Surrey K
    Allergy; 2005 Mar; 60(3):309-16. PubMed ID: 15679715
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The use of omalizumab in the treatment of severe allergic asthma: A clinical experience update.
    Holgate S; Buhl R; Bousquet J; Smith N; Panahloo Z; Jimenez P
    Respir Med; 2009 Aug; 103(8):1098-113. PubMed ID: 19362459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Mepolizumab for eosinophilic severe asthma: recent studies.
    Robinson DS; Kariyawasam HH
    Expert Opin Biol Ther; 2015 Jun; 15(6):909-14. PubMed ID: 25951938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Omalizumab for the treatment of exacerbations in children with inadequately controlled allergic (IgE-mediated) asthma.
    Lanier B; Bridges T; Kulus M; Taylor AF; Berhane I; Vidaurre CF
    J Allergy Clin Immunol; 2009 Dec; 124(6):1210-6. PubMed ID: 19910033
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Omalizumab: anti-IgE monoclonal antibody E25, E25, humanised anti-IgE MAb, IGE 025, monoclonal antibody E25, Olizumab, Xolair, rhuMAb-E25.
    BioDrugs; 2002; 16(5):380-6. PubMed ID: 12408744
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Omralizumab (Xolair) in severe persistent allergic asthma].
    Schleich F; Manise M; Louis R
    Rev Med Liege; 2009; 64(5-6):313-7. PubMed ID: 19642466
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.